{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wescott EC"],"funding":["U.S. Department of Defense (DOD)","NCI NIH HHS","HHS | NIH | National Cancer Institute (NCI)"],"pagination":["1120-1134"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11041871"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(4)"],"pubmed_abstract":["Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 family ligand with proposed immunosuppressive functions being explored as a cancer immunotherapy target and may be associated with anti-PD-L1 resistance. However, little is known about its regulation and effect on immune cell function in breast cancers. We assessed murine and human breast cancer cells to identify regulation mechanisms of B7-H4 in vitro. We used an immunocompetent anti-PD-L1-sensitive orthotopic mammary cancer model and induced ectopic expression of B7-H4. We assessed therapy response and transcriptional changes at baseline and under treatment"],"journal":["Cancer research communications"],"pubmed_title":["Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer."],"pmcid":["PMC11041871"],"funding_grant_id":["5P30CA068485","P01 CA210961","BC170037","5P50CA098131"],"pubmed_authors":["Hanna A","Bronzini J","Wulfkuhle J","Wescott EC","Taylor BC","Dees EC","Opalenik SR","Esserman LJ","Isaacs C","Sanchez V","Wilson JT","Ballinger TJ","Bharti V","Santa-Maria CA","Shah PD","Petricoin EF","Balko JM","van ˈt Veer LJ","Hirst GL","Brown Swigart L","Pietenpol JA","Lehmann BD","Sun X","Abramson VG","Sanders ME","Gallagher RI","Gomez H","Gonzalez-Ericsson P"],"additional_accession":[]},"is_claimable":false,"name":"Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.","description":"Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 family ligand with proposed immunosuppressive functions being explored as a cancer immunotherapy target and may be associated with anti-PD-L1 resistance. However, little is known about its regulation and effect on immune cell function in breast cancers. We assessed murine and human breast cancer cells to identify regulation mechanisms of B7-H4 in vitro. We used an immunocompetent anti-PD-L1-sensitive orthotopic mammary cancer model and induced ectopic expression of B7-H4. We assessed therapy response and transcriptional changes at baseline and under treatment","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-05-29T12:38:47.411Z","creation":"2026-04-08T04:47:55.508Z"},"accession":"S-EPMC11041871","cross_references":{"pubmed":["38687247"],"doi":["10.1158/2767-9764.CRC-23-0468"]}}